Genmab — August 2019
-
that the royalty income increased a lot more than the actual underlying base sales from Janssen. So in rough terms, we made about DKK 50 million extra on the FX gain on the royalty in Q1.
But if you think about it, DKK 50 million on a total revenue over the year of DKK 4.6 billion at this stage it's not material. Then we'll continue to look at that. I mean we like to be transparent. We do put down the rates that we're using. And I know in some of the consensus numbers, people are assuming a
-
higher rate.
The only last thing I'd point out is, don't forget that there is actually European sales of DARZALEX. Those are getting converted into U.S. dollars as Janssen's functional currency. And you will have seen that in the first quarter Janssen reported sales of DARZALEX rest of world increasing by 65%. But on a constant dollar basis, they said it would have been 80%.
So you do have some sort of round-robin calculation there where you get European euro sales for DARZALEX getting
-
Børsen har også opdaget det..:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind